Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists

Journal of Bone and Mineral Research

Volumn 28, Issue 1, 2013, Pages 92-107

  Lozano Ondoua, Alysia N ^a   Hanlon, Katherine E ^a   Symons Liguori, Ashley M ^a   Largent Milnes, Tally M ^a   Havelin, Josh J ^b   Ferland III, Henry L ^b   Chandramouli, Anupama ^a   Owusu Ankomah, Mabel ^a   Nikolich Zugich, Tijana ^a   Bloom, Aaron P ^a   Jimenez Andrade, Juan Miguel ^a   King, Tamara ^a,b   Porreca, Frank ^a,b   Nelson, Mark A ^a   Mantyh, Patrick W ^a   Vanderah, Todd W ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

BONE; CANCER; CANNABINOID 2 RECEPTOR; CHEMOKINE; CYTOKINE; PAIN

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; CANNABINOID 2 RECEPTOR;

ADVERSE OUTCOME; ANIMAL CELL; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG SAFETY; FEMUR; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOLYSIS; TUMOR VOLUME;

ANIMALS; BODY WEIGHT; BONE REMODELING; BONE RESORPTION; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; FRACTURES, BONE; INDOLES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; PAIN; RECEPTOR, CANNABINOID, CB2; SURVIVAL ANALYSIS;

EID: 84872849804     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1732     Document Type: Article

References (80)

1. American Cancer Society. Cancer Facts & Figures, 2010 [Internet]. Atlanta, GA, USA: American Cancer Society; 2010 [cited 2012 Aug 5]. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc- 024113.pdf.
2. Coleman RE,. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15; 12 (20 Pt 2): 6243s-9s.
3. DeNardo DG, Johansson M, Coussens LM,. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008 Mar; 27 (1): 11-8.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26; 363 (9): 809-19.
5. Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS,. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012 Jun 1; 30 (16): 1980-8.
6. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A,. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10; 28 (35): 5132-9.
7. Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK,. Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010 Oct 1; 27 (10): 775-89.
8. Altman RD, Latta LL, Keer R, Renfree K, Hornicek FJ, Banovac K,. Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma. 1995; 9 (5): 392-400.
9. Wilkinson AN, Viola R, Brundage MD,. Managing skeletal related events resulting from bone metastases. BMJ. 2008; 337: a2041.
10. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE, Vanderah TW, Lai J, Porreca F,. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007 Nov; 132 (1-2): 154-68.
11. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP Jr, Ossipov MH, Lai J, Porreca F,. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000 Sep 15; 20 (18): 7074-9.
12. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F,. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Curr Opin Pharmacol. 2003 Feb; 3 (1): 62-7.
13. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr., Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003 Sep 2; 100 (18): 10529-33.
14. Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A, Frenkel B, Shohami E, Bab I,. CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res. 2011 Feb; 26 (2): 308-16.
15. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, immer A, Bab I,. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006 Jan 17; 103 (3): 696-701.
16. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A,. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005 Nov 15; 14 (22): 3389-96.
17. Caffarel MM, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G, Flores JM, Garcia-Real I, Palacios J, Manes S, Guzman M, Sanchez C,. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010; 9: 196.
18. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P,. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol. 2007 Oct; 293 (4): H2210-8.
19. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H,. The cannabinoid system and immune modulation. J Leukoc Biol. 2003 Oct; 74 (4): 486-96.
20. Massi P, Vaccani A, Parolaro D,. Cannabinoids, immune system and cytokine network. Curr Pharm Des. 2006; 12 (24): 3135-46.
21. Coussens LM, Werb Z,. Inflammatory cells and cancer: think different!. J Exp Med. 2001 Mar 19; 193 (6): F23-6.
22. Fidler IJ,. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003 Jun; 3 (6): 453-8.
23. Costa L, Badia X, Chow E, Lipton A, Wardley A,. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008 Aug; 16 (8): 879-89.
24. Costa L, Major PP,. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009 Mar; 6 (3): 163-74.
25. Portenoy RK, Lesage P,. Management of cancer pain. Lancet. 1999 May 15; 353 (9165): 1695-700.
26. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K,. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010 Nov; 19 (6): 755-60.
27. Ohtori S, Takahashi K, Moriya H, Myers RR,. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (PhilaPa 1976). 2004 May 15; 29 (10): 1082-8.
28. Towbin H, Staehelin T, Gordon J,. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep; 76 (9): 4350-4.
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR,. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4; 82 (13): 1107-12.
30. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW,. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999 Dec 15; 19 (24): 10886-97.
31. Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F, King T,. Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain. 2011; 7: 81-96.
32. Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW,. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci. 2010 Apr 24; 86 (17-18): 646-53.
33. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL,. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994 Jul; 53 (1): 55-63.
34. Dixon WJ,. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol. 1980; 20: 441-62.
35. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW,. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 2001 May 15; 61 (10): 4038-47.
36. Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW,. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res. 2007 Nov; 22 (11): 1732-42.
37. Tang P, Hicks DG,. The histopathology of skeletal metastases. In:, D Heyman, editor Bone cancer: progression and therapeutic approaches. New York: Elsevier; 2010: p. 243-50.
38. Coleman RE,. Skeletal complications of malignancy. Cancer. 1997 Oct 15; 80: (8 Suppl): 1588-94.
39. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ,. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000 Mar 1; 88 (5): 1082-90.
40. Abrahm JL, Banffy MB, Harris MB,. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life ". JAMA. 2008 Feb 27; 299 (8): 937-46.
41. Chang JT, Green L, Beitz J,. Renal failure with the use of zoledronic acid. N Engl J Med. 2003 Oct 23; 349 (17): 1676-9 discussion 1676-9.
42. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS,. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007 Mar 15; 109 (6): 1090-6.
43. Luger NM, Mach DB, Sevcik MA, Mantyh PW,. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage. 2005 May; 29: (5 Suppl): S32-46.
44. Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH,. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?. Pharmacol Ther. 2006 Oct; 112 (1): 116-38.
45. Balkwill F, Coussens LM,. Cancer: an inflammatory link. Nature. 2004 Sep 23; 431 (7007): 405-6.
46. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002 Dec 19-26; 420 (6917): 860-7.
47. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH,. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol. 1992 Nov; 107 (3): 660-4.
48. Cunha JM, Cunha FQ, Poole S, Ferreira SH,. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol. 2000 Jul; 130 (6): 1418-24.
49. Hiratsuka S, Watanabe A, Aburatani H, Maru Y,. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006 Dec; 8 (12): 1369-75.
50. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ,. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001 Mar 22; 410 (6827): 471-5.
51. Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, Ferreira SH,. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A. 2005 Feb 1; 102 (5): 1755-60.
52. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S,. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 1997 Jun; 121 (3): 417-24.
53. Lunn CA, Fine J, Rojas-Triana A, Jackson JV, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L,. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss. Immunopharmacol Immunotoxicol. 2007; 29 (3-4): 387-401.
54. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA,. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology. 2008 Apr; 108 (4): 722-34.
55. Cravatt BF, Lichtman AH,. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004 Oct; 61 (1): 149-60.
56. Gkoumassi E, Dekkers BG, Droge MJ, Elzinga CR, Schmidt M, Meurs H, Zaagsma J, Nelemans SA,. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br J Pharmacol. 2007 Aug; 151 (7): 1041-8.
57. White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, Lamotte RH, Miller RJ,. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A. 2005 Sep 27; 102 (39): 14092-7.
58. Kiguchi N, Kobayashi Y, Kishioka S,. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012 Feb; 12 (1): 55-61.
59. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ,. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A. 2003 Jun 24; 100 (13): 7947-52.
60. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH,. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991 Nov; 104 (3): 765-7.
61. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ,. A proinflammatory chemokine, CCL3, sensitizes the heat-and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A. 2005 Mar 22; 102 (12): 4536-41.
62. Mundy GR, Yoneda T,. Facilitation and suppression of bone metastasis. Clin Orthop Relat Res. 1995 Mar (312): 34-44.
63. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP,. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002 Mar; 2 (3): 201-9.
64. George KL, Saltman LH, Stein GS, Lian JB, Zurier RB,. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol. 2008 Mar; 214 (3): 714-20.
65. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K,. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr; 13 (2): 165-74.
66. Scadding JW,. The permanent anatomical effects of neonatal capsaicin on somatosensory nerves. J Anat. 1980 Oct; 131 (Pt 3): 471-82.
67. Hill EL, Turner R, Elde R,. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience. 1991; 44 (3): 747-55.
68. Ben-Baruch A,. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006 Sep; 25 (3): 357-71.
69. Hodge DR, Hurt EM, Farrar WL,. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005 Nov; 41 (16): 2502-12.
70. Karin M, Lawrence T, Nizet V,. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006 Feb 24; 124 (4): 823-35.
71. Grivennikov S, Karin M,. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell. 2008 Jan; 13 (1): 7-9.
72. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR,. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005 Jul 15; 175 (2): 1197-205.
73. Szlosarek P, Charles KA, Balkwill FR,. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006 Apr; 42 (6): 745-50.
74. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F,. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011; 2011: 5651-87.
75. Maghazachi AA,. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol. 2010; 341: 37-58.
76. Ellert-Miklaszewska A, Kaminska B, Konarska L,. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 2005 Jan; 17 (1): 25-37.
77. Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Liorente-Berzal A, Viveros MP, Ishiguro H, Arinami T, Onaivi ES, Uhl GR,. Species differences in cannabinoid receptor 2 (CNR2 gene): Identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009; 8 (5): 519-30.
78. Allen JM,. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care. 2010 Sep; 16 (9): 697-704.
79. Mercadante S,. Malignant bone pain: pathophysiology and treatment. Pain. 1997 Jan; 69 (1-2): 1-18.
80. Harmon A,. Target cancer. New drugs stir debate on rules of clinical trials [Internet]. New York (NY): New York Times (New York edition); 2010 Sep 19:A1 [cited 2012 Sep 5]. Available from: http://www.nytimes.com/2010/09/19/ health/research/19trial.html?pagewanted=all#.